Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a development milestone in its collaboration with Eli Lilly and Company. In accordance with Zymeworks’ 2013 licensing and collaboration agreement with Lilly, Zymeworks will …
Latest News From Lumira Ventures
Corvia Medical Announces Strong Positive One-Year Data From REDUCE LAP-HF I Randomized, Sham-Controlled Clinical Trial
Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced one-year follow-up data from the REDUCE LAP-HF I clinical study of its Interatrial Shunt Device (IASD®). The IASD is the world’s first …
Forbius (Formation Biologics) Awarded $18.8 Million Grant by the Cancer Prevention and Research Institute of Texas
Forbius (Formation Biologics) announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant will support operations and Phase 2a development of AVID100, a highly …
Forbius’ AVID200 IND Receives Clearance from the FDA to Start Phase 1 Scleroderma Clinical Trial
Forbius announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for AVID200, an isoform-selective TGF-β inhibitor. This enables the company to begin a Phase 1 clinical study to evaluate AVID200 as a potential treatment for diffuse cutaneous systemic …
Antiva Biosciences – A women’s health startup tried to drum up interest for a much-needed drug. Many men didn’t get it
August 16, 2018 External Link
Celtaxsys Cystic Fibrosis Drug Reduces Key Symptom in Mid-stage Study
(Reuters) – Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function. There are few treatment …
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
Acebilustat is the first novel anti-inflammatory molecule evidencing the potential to reduce frequency of pulmonary exacerbations and prolong time to first exacerbation in CF patients Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing …
Aurinia Pharmaceuticals to Release Second Quarter 2018 Financial Results on August 9, 2018
VICTORIA, British Columbia– Aurinia Pharmaceuticals Inc. today announced that it will release its second quarter 2018 financial results on Thursday, August 9, 2018, after the market closes. Aurinia’s management will host a conference call to discuss the company’s second quarter …
Exact Imaging becomes UroGPO Imaging Partner By Providing Micro-Ultrasound Based Targeting Solution for Prostate Biopsies
Relationship allows UroGPO’s 550+ Member Practices across the USA to access the ExactVu™ Micro-Ultrasound Platform TORONTO, CANADA – Exact Imaging, the world’s leader in high resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, announced today that it …
BAROnova Announces Submission of Premarket Approval (PMA) Application to the U.S. FDA for the TransPyloric Shuttle® (TPS®) Device Intended for the Treatment of Obesity
SAN CARLOS, Calif., /PRNewswire/ — BAROnova, Inc., announced today that it has submitted a Pre-Market Approval (PMA) application for the TransPyloric Shuttle device intended for the treatment of obesity to the Food and Drug Administration (FDA). Obesity is a worldwide epidemic with …
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
MONTRÉAL and BOSTON, /CNW/ – enGene Inc., a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs, including the Gene Pill™ , today announced the appointment of Jason D. Hanson as President, Chief Executive Officer and …
Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome
VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the initiation of its Phase 2 trial evaluating voclosporin ophthalmic solution (VOS) for the treatment of dry eye …
Antiva Biosciences Closes $15 Million Series C-1 Financing
SOUTH SAN FRANCISCO, California, /PRNewswire/ — Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has raised $15 million in Series C-1 financing led by Hillhouse Capital Management. Sirona …
G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel
RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as …
Aurinia: Teamwork Twice
Source: Life Science Leader By Wayne Koberstein, Executive Editor, Life Science Leader magazineFollow Me On Twitter @WayneKoberstein The Enterprisers: Life Science Leadership In Action External Link